On behalf of the organizing committee, we cordially invite you to attend the World ROP Congress Ⅲ, an international conference on retinopathy of prematurity to be held in October14-16, 2012, in Shanghai, China.
Description of a clinical phase II trial with IGF-I/IGFBP-3 supplementation
....pharmacokinetic study of intravenously administered rhIGF-I/rhIGFBP-3 complex (mecasermin rinfabate) to five very preterm children (GA 26-29 weeks). No side effects (b-glucose, heart rate, blood pressure) were seen...
The web site for the 3rd World ROP Congress offers a download of an 'all you need to know' guide to the event.
Around 130 people made presentations, and the guide finishes with a long section of abstracts of the presentations. All of the early abstracts I checked included a description, results and conclusions - so I rather nervously waded through them all until I finally found the important one -
"Description of a clinical phase II trial with IGF-I/IGFBP-3 supplementation.
A large number of risk factors have been identified Low neonatal serum IGF-I is closely related to later ROP and a study of supplementation with rhIGF-I (NCT01096784) is currently taking place and will be discussed."
I didn't bother to check if that was the only abstract (of the 130) which told the reader little more than was obvious from the title.
Hmm ..... the share price hit that recent high of $7.14 on October 9, just a few days before she would have made that presentation.
That may have been a very revealing session.
The primary outcome measure in this study is the severity of ROP - measured as each baby reaches what would have been considered "full term" had the baby not been born prematurely.
But weight, length, head circumference and brain size are measured at birth, and then at least twice-weekly thereafter. The baby's weight gain is measured on each of the first three days after birth (and thereafter twice-weekly).
When Ann made that presentation she would have KNOWN if the babies have been developing at a rate which is closer to that of babies still in the womb than that of babies born prematurely.
Even if the therapy was to make zero difference to the severity of ROP it would still be widely used if it significantly reduced the average time spent in neonatal intensive care units.
The experts in the audience would almost certainly have asked her about the rate of weight gain.
This is another Insmed therapy I could see the Chinese government buying in bulk via our good buddy Merck. With a population of 1.3 billion, 95% healthcare coverage, and a government which is throwing billions into an initiative to provide better healthcare, good news on the weight gain could be very good news for us as well.